⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418272 | 1.00 | — | — | |
| SCHEMBL4320800 | 1.00 | — | — | |
| SCHEMBL3439179 | 0.75 | — | — | |
| SCHEMBL7511925 | 0.75 | — | — | |
| SCHEMBL3439154 | 0.75 | — | — | |
| SCHEMBL28504597 | 0.75 | — | — | |
| SCHEMBL5250595 | 0.75 | — | — | |
| SCHEMBL5366751 | 0.71 | — | — | |
| SCHEMBL8860061 | 0.70 | — | — | |
| SCHEMBL8860014 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103228142-A | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | UNIV CALIFORNIA | 2013-07-31 | — | — | CN | claimed |
| CN-1200713-C | New (aminopropyl) methylphosphinic acids | ASTRAZENECA AB (SE) | 2005-05-11 | — | — | CN | claimed |
| CN-1413104-A | New (aminopropyl) methylphosphinic acids | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | CN | claimed |
| US-20250082654-A1 | AZD3355 (LESOGABERAN) FOR TREATMENT AND PREVENTION OF NONALCOHOLIC STEATOHEPATITIS (NASH), LIVER FIBROSIS, AND OTHER LIVER CONDITIONS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-03-13 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-107050456-B | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | 加利福尼亚大学董事会 | 2022-08-12 | — | — | CN | disclosed |
| US-20210330684-A1 | AZD3355 (LESOGABERAN) FOR TREATMENT AND PREVENTION OF NONALCOHOLIC STEATOHEPATITIS (NASH), LIVER FIBROSIS, AND OTHER LIVER CONDITIONS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2021-10-28 | — | — | US | disclosed |
| EP-3863643-A1 | AZD3355 (LESOGABERAN) FOR TREATMENT AND PREVENTION OF NONALCOHOLIC STEATOHEPATITIS (NASH), LIVER FIBROSIS, AND OTHER LIVER CONDITIONS | Icahn School of Medicine at Mount Sinai (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-103228142-A | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | UNIV CALIFORNIA | 2013-07-31 | — | — | CN | disclosed |
| CN-101743011-A | The use of (3-amino-2-fluoropropyl) phosphinic acid for treatment of nerd | ASTRAZENECA AB | 2010-06-16 | — | — | CN | disclosed |
| WO-2009145716-A1 | NEW PHARMACEUTICAL FORMULATION USEFUL IN GERD THERAPY | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| CN-101087614-A | New use of GABAbeta receptor agonists | ASTRAZENECA AB (SE) | 2007-12-12 | — | — | CN | disclosed |
| US-20060160777-A1 | New use of GABAbeta receptor agonists | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | US | disclosed |
| CN-1200713-C | New (aminopropyl) methylphosphinic acids | ASTRAZENECA AB (SE) | 2005-05-11 | — | — | CN | disclosed |
| CN-1413104-A | New (aminopropyl) methylphosphinic acids | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | CN | disclosed |